The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition. To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.
Study Type
OBSERVATIONAL
Enrollment
1,600
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
RECRUITINGGene sequencing
DNA sequence variants
Time frame: Recurrence free survival at 2 years
Gene expression analysis
Differentially expressed genes
Time frame: Recurrence free survival at 2 years
Status of genome-wide chromatin accessibility
chromatin accessibility
Time frame: Duration of active chemotherapy to two years after surgical treatment
Epigenetic change
Differential methylation
Time frame: Duration of active chemotherapy to two years after surgical treatment
Tumor infiltrating cells which express immune checkpoints
differentially enriched immune cells
Time frame: Duration of active chemotherapy to two years after surgical treatment
Response to chemotherapy
Survival
Time frame: Duration of active chemotherapy to two years after surgical treatment
Response to chemotherapy
Relapse
Time frame: Duration of active chemotherapy to two years after surgical treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.